DekaBank Deutsche Girozentrale Has $203.35 Million Holdings in Bristol-Myers Squibb (NYSE:BMY)

DekaBank Deutsche Girozentrale cut its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 1.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,950,080 shares of the biopharmaceutical company’s stock after selling 56,542 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Bristol-Myers Squibb were worth $203,347,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of BMY. OFI Invest Asset Management acquired a new position in shares of Bristol-Myers Squibb in the 3rd quarter valued at $25,000. True Wealth Design LLC bought a new stake in Bristol-Myers Squibb in the fourth quarter valued at about $26,000. Milestone Investment Advisors LLC acquired a new position in Bristol-Myers Squibb in the third quarter worth about $27,000. Coppell Advisory Solutions LLC bought a new position in Bristol-Myers Squibb during the second quarter worth about $28,000. Finally, Blue Bell Private Wealth Management LLC boosted its holdings in Bristol-Myers Squibb by 61.5% during the third quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 200 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol-Myers Squibb Trading Down 0.2 %

NYSE:BMY traded down $0.08 on Friday, reaching $51.32. The company’s stock had a trading volume of 9,085,611 shares, compared to its average volume of 18,614,780. The firm has a market cap of $104.01 billion, a PE ratio of 13.30, a PEG ratio of 1.55 and a beta of 0.39. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.31 and a current ratio of 1.43. The business’s 50-day moving average price is $51.19 and its two-hundred day moving average price is $52.10. Bristol-Myers Squibb has a 1-year low of $47.58 and a 1-year high of $71.07.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.55 by $0.15. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. The business had revenue of $11.48 billion during the quarter, compared to analyst estimates of $11.19 billion. During the same period in the previous year, the firm earned $1.82 EPS. Bristol-Myers Squibb’s quarterly revenue was up .6% compared to the same quarter last year. Equities research analysts anticipate that Bristol-Myers Squibb will post 6.63 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be paid a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 4.68%. The ex-dividend date of this dividend is Thursday, April 4th. Bristol-Myers Squibb’s payout ratio is 62.18%.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on BMY shares. William Blair reissued a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. StockNews.com raised shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Friday, March 1st. Societe Generale cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. Bank of America cut shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their target price for the company from $68.00 to $60.00 in a research note on Wednesday, January 3rd. Finally, Wells Fargo & Company dropped their price target on Bristol-Myers Squibb from $58.00 to $51.00 and set an “equal weight” rating for the company in a report on Tuesday, February 6th. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Bristol-Myers Squibb has a consensus rating of “Hold” and a consensus target price of $61.12.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.